Organoid cultures derived from patients with advanced prostate cancer

Cell

Volumn 159, Issue 1, 2014, Pages 176-187

  Gao, Dong ^a   Vela, Ian ^a   Sboner, Andrea ^b,c   Iaquinta, Phillip J ^a   Karthaus, Wouter R ^d   Gopalan, Anuradha ^a   Dowling, Catherine ^a   Wanjala, Jackline N ^a   Undvall, Eva A ^a   Arora, Vivek K ^a   Wongvipat, John ^a   Kossai, Myriam ^c   Ramazanoglu, Sinan ^b,c   Barboza, Luendreo P ^a   Di, Wei ^a   Cao, Zhen ^a   Zhang, Qi Fan ^a   Sirota, Inna ^a   Ran, Leili ^a   Macdonald, Theresa Y ^c   Beltran, Himisha ^c   Mosquera, Juan Miguel ^c   Touijer, Karim A ^a   Scardino, Peter T ^a   Laudone, Vincent P ^a   Curtis, Kristen R ^a   Rathkopf, Dana E ^a,c   Morris, Michael J ^a,c   Danila, Daniel C ^a,c   Slovin, Susan F ^a,c   Solomon, Stephen B ^a   Eastham, James A ^a   Chi, Ping ^a,c   Carver, Brett ^a   Rubin, Mark A ^c   Scher, Howard I ^a,c   Clevers, Hans ^d   Sawyers, Charles L ^a,e   Chen, Yu ^a,c   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 1 GENE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; FOXA1 GENE; FUSION GENE; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN CULTURE; PIK3R1 GENE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SPINK1 GENE; SPOP GENE; TMPRSS2 ERG FUSION GENE; TUMOR GENE; TUMOR XENOGRAFT; CELL CULTURE TECHNIQUE; CYTOPLASM; METABOLISM; METASTASIS; PATHOLOGY; PHARMACOLOGY; PROCEDURES; PROSTATE TUMOR; XENOGRAFT;

CULTURE TECHNIQUES; HETEROGRAFTS; HUMANS; MALE; NEOPLASM METASTASIS; ORGANOIDS; PHARMACOLOGY; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84907554319     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2014.08.016     Document Type: Article

References (47)

1. V.K. Arora, E. Schenkein, R. Murali, S.K. Subudhi, J. Wongvipat, M.D. Balbas, N. Shah, L. Cai, E. Efstathiou, and C. Logothetis Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Cell 155 2013 1309 1322
2. S.C. Baca, D. Prandi, M.S. Lawrence, J.M. Mosquera, A. Romanel, Y. Drier, K. Park, N. Kitabayashi, T.Y. MacDonald, and M. Ghandi Punctuated evolution of prostate cancer genomes Cell 153 2013 666 677
3. M.D. Balbas, M.J. Evans, D.J. Hosfield, J. Wongvipat, V.K. Arora, P.A. Watson, Y. Chen, G.L. Greene, Y. Shen, and C.L. Sawyers Overcoming mutation-based resistance to antiandrogens with rational drug design eLife 2 2013 e00499
4. C.E. Barbieri, S.C. Baca, M.S. Lawrence, F. Demichelis, M. Blattner, J.P. Theurillat, T.A. White, P. Stojanov, E. Van Allen, and N. Stransky Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat. Genet. 44 2012 685 689
5. N. Barker, M. Huch, P. Kujala, M. van de Wetering, H.J. Snippert, J.H. van Es, T. Sato, D.E. Stange, H. Begthel, and M. van den Born Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro Cell Stem Cell 6 2010 25 36
6. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, S. Kim, C.J. Wilson, J. Lehár, G.V. Kryukov, and D. Sonkin The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
7. H. Beltran, D.S. Rickman, K. Park, S.S. Chae, A. Sboner, T.Y. MacDonald, Y. Wang, K.L. Sheikh, S. Terry, and S.T. Tagawa Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets Cancer Discov 1 2011 487 495
8. L. Burkhardt, S. Fuchs, A. Krohn, S. Masser, M. Mader, M. Kluth, F. Bachmann, H. Huland, T. Steuber, and M. Graefen CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer Cancer Res. 73 2013 2795 2805
9. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
10. B.S. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen, S. Chandarlapaty, V.K. Arora, C. Le, J. Koutcher, and H. Scher Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
11. E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, A. Jacobsen, C.J. Byrne, M.L. Heuer, and E. Larsson The cBiol. cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov. 2 2012 401 404
12. Y. Chen, P. Chi, S. Rockowitz, P.J. Iaquinta, T. Shamu, S. Shukla, D. Gao, I. Sirota, B.S. Carver, and J. Wongvipat ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss Nat. Med. 19 2013 1023 1029
13. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr., F. Saad COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer N. Engl. J. Med. 364 2011 1995 2005
14. F. Demichelis, S.R. Setlur, R. Beroukhim, S. Perner, J.O. Korbel, C.J. Lafargue, D. Pflueger, C. Pina, M.D. Hofer, and A. Sboner Distinct genomic aberrations associated with ERG rearranged prostate cancer Genes Chromosomes Cancer 48 2009 366 380
15. A. Dobin, C.A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski, S. Jha, P. Batut, M. Chaisson, and T.R. Gingeras STAR: ultrafast universal RNA-seq aligner Bioinformatics 29 2013 15 21
16. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, J. Zimmermann, and N.B. Lydon Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat. Med. 2 1996 561 566
17. M.J. Garnett, E.J. Edelman, S.J. Heidorn, C.D. Greenman, A. Dastur, K.W. Lau, P. Greninger, I.R. Thompson, X. Luo, and J. Soares Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 2012 570 575
18. C.S. Grasso, Y.M. Wu, D.R. Robinson, X. Cao, S.M. Dhanasekaran, A.P. Khan, M.J. Quist, X. Jing, R.J. Lonigro, and J.C. Brenner The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
19. J.S. Horoszewicz, S.S. Leong, E. Kawinski, J.P. Karr, H. Rosenthal, T.M. Chu, E.A. Mirand, and G.P. Murphy LNCaP model of human prostatic carcinoma Cancer Res. 43 1983 1809 1818
20. M. Huch, P. Bonfanti, S.F. Boj, T. Sato, C.J. Loomans, M. van de Wetering, M. Sojoodi, V.S. Li, J. Schuijers, and A. Gracanin Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis EMBO J. 32 2013 2708 2721
21. M. Huch, C. Dorrell, S.F. Boj, J.H. van Es, V.S. Li, M. van de Wetering, T. Sato, K. Hamer, N. Sasaki, and M.J. Finegold In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration Nature 494 2013 247 250
22. H. Johnson, M. Zhou, and A.O. Osunkoya ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma Hum. Pathol. 44 2013 2241 2246
23. M.E. Kaighn, J.F. Lechner, K.S. Narayan, and L.W. Jones Prostate carcinoma: tissue culture cell lines Natl. Cancer Inst. Monogr. 49 1978 17 21
24. W.R. Karthaus, P.J. Iaquinta, J. Drost, A. Gracanin, R. van Boxtel, J. Wongvipat, C.M. Dowling, D. Gao, H. Begthel, and N. Sachs Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures Cell 158 2014 10.1016/j.cell.2014.08.017 Published online September 4, 2014
25. S. Korenchuk, J.E. Lehr, L. MClean, Y.G. Lee, S. Whitney, R. Vessella, D.L. Lin, and K.J. Pienta VCaP, a cell-based model system of human prostate cancer In Vivo 15 2001 163 168
26. A. Krohn, A. Seidel, L. Burkhardt, F. Bachmann, M. Mader, K. Grupp, T. Eichenauer, A. Becker, M. Adam, and M. Graefen Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers J. Pathol. 231 2013 130 141
27. A. Kumar, T.A. White, A.P. MacKenzie, N. Clegg, C. Lee, R.F. Dumpit, I. Coleman, S.B. Ng, S.J. Salipante, and M.J. Rieder Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers Proc. Natl. Acad. Sci. USA 108 2011 17087 17092
28. H. Li, and R. Durbin Fast and accurate long-read alignment with Burrows-Wheeler transform Bioinformatics 26 2010 589 595
29. W. Liu, J. Lindberg, G. Sui, J. Luo, L. Egevad, T. Li, C. Xie, M. Wan, S.T. Kim, and Z. Wang Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer Oncogene 31 2012 3939 3948
30. X. Liu, V. Ory, S. Chapman, H. Yuan, C. Albanese, B. Kallakury, O.A. Timofeeva, C. Nealon, A. Dakic, and V. Simic ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells Am. J. Pathol. 180 2012 599 607
31. A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, and M.A. DePristo The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data Genome Res. 20 2010 1297 1303
32. K.D. Mertz, S.R. Setlur, S.M. Dhanasekaran, F. Demichelis, S. Perner, S. Tomlins, J. Tchinda, B. Laxman, R.L. Vessella, and R. Beroukhim Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model Neoplasia 9 2007 200 206
33. N.M. Navone, M. Olive, M. Ozen, R. Davis, P. Troncoso, S.M. Tu, D. Johnston, A. Pollack, S. Pathak, A.C. von Eschenbach, and C.J. Logothetis Establishment of two human prostate cancer cell lines derived from a single bone metastasis Clin. Cancer Res. 3 1997 2493 2500
34. A.V. Parwani, J.D. Kronz, E.M. Genega, P. Gaudin, S. Chang, and J.I. Epstein Prostate carcinoma with squamous differentiation: an analysis of 33 cases Am. J. Surg. Pathol. 28 2004 651 657
35. D. Rathkopf, and H.I. Scher Androgen receptor antagonists in castration-resistant prostate cancer Cancer J. 19 2013 43 49
36. A. Roberts, C. Trapnell, J. Donaghey, J.L. Rinn, and L. Pachter Improving RNA-Seq expression estimates by correcting for fragment bias Genome Biol. 12 2011 R22
37. C.J. Ryan, M.R. Smith, J.S. De Bono, A. Molina, C. Logothetis, P.L. De Souza, K. Fizazi, P.N. Mainwaring, J.M. Piulats Rodriguez, and S. Ng Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) ASCO Meeting Abstracts 30 2012 LBA4518
38. T. Sato, R.G. Vries, H.J. Snippert, M. van de Wetering, N. Barker, D.E. Stange, J.H. van Es, A. Abo, P. Kujala, P.J. Peters, and H. Clevers Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche Nature 459 2009 262 265
39. L.A. Schelling, S.R. Williamson, S. Zhang, J.L. Yao, M. Wang, J. Huang, R. Montironi, A. Lopez-Beltran, R.E. Emerson, and M.T. Idrees Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry Hum. Pathol. 44 2013 2227 2233
40. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy N. Engl. J. Med. 367 2012 1187 1197
41. A. Sharma, W.S. Yeow, A. Ertel, I. Coleman, N. Clegg, C. Thangavel, C. Morrissey, X. Zhang, C.E. Comstock, and A.K. Witkiewicz The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression J. Clin. Invest. 120 2010 4478 4492
42. O. Smaletz, H.I. Scher, E.J. Small, D.A. Verbel, A. McMillan, K. Regan, W.K. Kelly, and M.W. Kattan Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J. Clin. Oncol. 20 2002 3972 3982
43. D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J.M. Lobo, Y. She, and I. Osman BRAF mutation predicts sensitivity to MEK inhibition Nature 439 2006 358 362
44. R.M. Sramkoski, T.G. Pretlow 2nd, J.M. Giaconia, T.P. Pretlow, S. Schwartz, M.S. Sy, S.R. Marengo, J.S. Rhim, D. Zhang, and J.W. Jacobberger A new human prostate carcinoma cell line, 22Rv1 In Vitro Cell. Dev. Biol. Anim. 35 1999 403 409
45. B.S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B.S. Carver, V.K. Arora, P. Kaushik, E. Cerami, and B. Reva Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
46. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. von Pawel, S. Thongprasert, E.H. Tan, K. Pemberton, V. Archer, and K. Carroll Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
47. S.A. Tomlins, D.R. Rhodes, J. Yu, S. Varambally, R. Mehra, S. Perner, F. Demichelis, B.E. Helgeson, B. Laxman, and D.S. Morris The role of SPINK1 in ETS rearrangement-negative prostate cancers Cancer Cell 13 2008 519 528